Stimulating pharmaceutical research and development for neglected diseases
Stimulating pharmaceutical research and development for neglected diseases
复制标题
DOI：
10.1016/s0168-8510(02)00138-0
复制
发表时间：
2003-04-01
期刊：
影响因子：
3.3
通讯作者：
Mossialos, E
中科院分区：
文献类型：
--
作者：
Mrazek, MF;Mossialos, E
需要新的疫苗和药物治疗来应对贫穷国家被忽视的疾病。这些疾病与高死亡率和/或发病率有关，但由于细菌耐药性、毒性、长期治疗方案、给药问题或因为没有可用的疫苗和药物，缺乏适当的疫苗和药物治疗。目前，针对新药研发的举措主要由政府、政府间和私营非营利部门牵头，通过公私伙伴关系实施。针对制药行业的推拉机制也被提议作为刺激ND研发的另一种方式;然而，这些应该谨慎看待。作为更广泛的长期公共卫生战略的一部分，刺激新药研发非常重要，必须与解决欠发达国家更紧迫的药品获取和卫生系统可持续性问题同时解决。(C)2002年由Elsevier Science爱尔兰有限公司出版。
New vaccines and drug treatments are needed for tackling the neglected diseases (NDs) of poor countries. These diseases are associated with high levels of mortality and/or morbidity, but lack appropriate vaccines and drug treatments because of bacterial resistance, toxicity, long-treatment protocols, problems with administration or because none are available. Current initiatives directed at research and development (R&D) of NDs are being led predominantly by the governmental, inter-governmental and private not-for-profit sectors implemented by way of public-private partnerships. Push and pull mechanisms targeted at the pharmaceutical industry have also been proposed as another way to stimulate RD of NDs; however, these should be viewed with some caution. Stimulating R&D for NDs is important as part of a wider long-term public health strategy and must be addressed simultaneously with resolving more immediate problems of access to medicines and health system sustainability in less developed countries. (C) 2002 Published by Elsevier Science Ireland Ltd.